CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The subject has a type of lymph gland cancer called Lymphoma. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected with germs. Both antibodies and T cells have been used to treat patients with cancers; they both have shown promise, but have not been strong enough to cure most patients. Investigators hope that both will work better together. Investigators have found from previous research that they can put a new gene into T cells that will make them recognize cancer cells and kill them. They now want to test whether these genetically modified T cells given after chemotherapy will be more effective at killing cancer cells. The gene that will be put into the T cells makes an antibody called anti-CD30. This antibody sticks to lymphoma cells because of a substance on the outside of the cells called CD30. Anti-CD30 antibodies have been used to treat people with lymphoma, but have not been strong enough to cure most patients. For this study, the anti-CD30 antibody has been changed so that instead of floating free in the blood it is now joined to the T cells. When an antibody is joined to a T cell in this way it is called a chimeric receptor. These CD30 chimeric receptor-activated T cells (CD30.CAR T cells) seem to kill some of the tumor, but they don't last very long and so their chances of fighting the cancer are unknown. Several studies suggest that the infused T cells need room to be able to multiply and grow to accomplish their functions, and that this may not happen if there are too many other T cells in circulation. Because of that, doctors may use chemotherapy drugs to decrease the level of circulating T cells prior to the CD30.CAR T cells infusion. This is called "lymphodepletion" CD30.CAR T cells have previously been studied in lymphoma patients.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Diagnoza nawracającego lub opornego na leczenie chłoniaka Hodgkina lub nie-Hodgkina.
- •Potwierdzenie obecności CD30 na komórkach nowotworowych.
- •Ogólny dobry stan zdrowia pacjenta (oceniany za pomocą skali Karnofsky'ego lub Lansky'ego).
- •Pacjent lub jego opiekun wyraża świadomą zgodę na udział w badaniu.
✗ Disqualifies
- •Aktywna infekcja (w tym HIV lub HTLV).
- •Przyjmowanie innych eksperymentalnych leków lub szczepionek przeciwnowotworowych w ciągu ostatnich sześciu tygodni.
- •Leczenie przeciwciałami anty-CD30 w ciągu ostatnich czterech tygodni.
Simplified criteria — AI translation
Trial details
- Minimum age
- 12 Years
- Maximum age
- 75 Years
- Last updated (source)
- October 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Houston Methodist Hospital
Houston, United States
Texas Children's Hospital
Houston, United States
Trial contact
Carlos A Ramos, MD
Vicky Torrano, RN
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.